Azitra is trading 5.32% down now at $0.16, primarily amid biotech-sector weakness, with no new company-specific adverse announcement identified for September 16, 2026.
- Biotech ETF XBI is down 2.11% as disappointing drug-trial news weakened sentiment across biotechnology.
- Azitra’s latest identified company update was its September 8 announcement regarding an H.C. Wainwright conference presentation, not a negative operating catalyst.